ALXN Alexion Pharmaceuticals Inc.

117
+2.71  (+2%)
Previous Close 114.29
Open 115.14
Price To Book 2.85
Market Cap 26102305944
Shares 223,096,632
Volume 2,472,844
Short Ratio
Av. Daily Volume 1,714,168

NewsSee all news

  1. Biotech Stock Dips On $700 Million Risk After European Patent Vote
  2. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  3. Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
  4. Why Sarepta Therapeutics Stock Is Starting to Shine Again
  5. Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

SEC filingsSee all SEC filings

  1. 8-K - Current report 181248250
  2. CT ORDER - Confidential treatment order 181237437
  3. 8-K - Current report 181188627
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176063
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181136698

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 primary endpoint met - September 24, 2018.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 data due early 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 trial is enrolling.
WTX101
Wilson disease

Latest News

  1. Biotech Stock Dips On $700 Million Risk After European Patent Vote
  2. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  3. Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
  4. Why Sarepta Therapeutics Stock Is Starting to Shine Again
  5. Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
  6. Three tech, three biotech companies that are top takeover targets in 2019
  7. Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT
  8. Why Alexion Pharmaceuticals Stock Fell 21% in December
  9. 4 Biotechs That Are Potential Buyouts Post Celgene Deal
  10. Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019
  11. Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference
  12. Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
  13. Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
  14. Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija
  15. Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference
  16. 'Santa Comes Early' As This Biotech Stock Grabs Its Fourth Approval

SEC Filings

  1. 8-K - Current report 181248250
  2. CT ORDER - Confidential treatment order 181237437
  3. 8-K - Current report 181188627
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181176063
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181136698
  6. 8-K - Current report 181135237
  7. 8-K - Current report 181098576
  8. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181018925
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972206
  10. 8-K - Current report 18970097